TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating ...

In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

In recent trading, Merck & Co Inc (MRK) stock price has shown some volatility, fluctuating -3.05% over the last five trades and -9.24% over the past 30 trades. This represents a notable shift from ...

Empowering young women with the confidence to excel in their education is key to inspiring the next generation' ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha ...

Utilization in fine chemical synthesis processes for the production of specialty chemicals and intermediates drives <a ...

Report with the AI impact on market trends- The global sexually transmitted disease (STD) testing market size is estimated to ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer aft ...